WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) has appointed Kent Taylor as senior vice president of sales to lead its U.S. commercial organization ahead of a potential product launch.
Taylor will oversee sales strategy and team development as the company prepares for a possible U.S. launch of QTORIN rapamycin, an investigational treatment for microcystic lymphatic malformations, a rare genetic condition with no approved therapies.
Taylor brings more than 25 years of experience in pharmaceutical sales and marketing, including leadership roles at Arcutis Biotherapeutics and Incyte.
At Arcutis, he led U.S. sales efforts for ZORYVE, while at Incyte he supported the launch of OPZELURA and built a dermatology-focused sales organization.
Chief Executive Officer Wes Kaupinen said Taylor’s experience in dermatology and product launches aligns with the company’s commercial plans.
“Kent’s dermatology experience complements the rare disease commercial leadership we have assembled at Palvella,” Kaupinen said.
Taylor said the role will focus on building a sales organization to support potential commercialization of the company’s lead therapy.
“I am excited to build on that foundation and establish an exceptional sales organization in preparation for the potential U.S. launch of QTORIN rapamycin,” Taylor said.
Palvella is developing therapies for rare skin diseases and vascular malformations, including its lead candidate QTORIN rapamycin gel for multiple indications.
Microcystic lymphatic malformations affect more than 30,000 diagnosed patients in the United States, according to the company.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.